One hedge fund is on a winning streak when it comes to takeovers of companies Deutsche Bank Office company headquarters picturedeveloping hepatitis C treatments.

QVT Financial, started by ex-Deutsche Bank prop traders, is among the largest shareholders of Inhibitex, which agreed over the weekend to a $2.5 billion acquisition by Bristol-Myers Squibb.

According to regulatory filings, QVT first bought shares for about $1 each in 2009, and also took warrants to acquire millions more shares at $1.46 each. That means QVT’s stock is worth about $105 million at Bristol-Myers’s takeover price, or very roughly 25 times what QVT paid for its investment in 2009.

http://blogs.wsj.com/deals/2012/01/09/this-hedge-fund-has-made-a-fortune-on-hepatitis-c-companies/?mod=WSJBlog

ValueWalk Premium Subscription Includes:

  • 3 Write-ups per month (EXCLUSIVE content that you won’t find anywhere else)
  • Personal Track Record from Jacob’s Brokerage
  • Any question you have answered within 48 hours